

Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)

Samsara Vision Attending American Academy of Ophthalmology (AAO) 2025

FAR HILLS, N.J.--(BUSINESS WIRE)-- Samsara Vision, a company focused on bringing vision and freedom back to patients with late-stage, age-related macular degeneration (AMD) through advanced visual prosthetic devices, today announced the expansion of its ongoing Concerto clinical study evaluating the investigational Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®). Four new clinical sites recently opened across the United States and Puerto Rico, thereby increasing access to eligible study candidates, aged 65 and older, living with late-stage AMD.

There are now thirteen Concerto clinical trials sites across the United States and Puerto Rico. Samsara Vision is attending the American Academy of Ophthalmology annual meeting (AAO 2025 – booth #1803) to directly connect with providers about Concerto and offer insights about the SING IMT in CE referenced countries where it is already approved and available for use. The sites recently joining the study include:

- Cincinnati Eye Institute (Cincinnati, OH) Principal Investigator: Michael Snyder, MD
- Georgia Eye Partners (Woodstock, GA) Principal Investigator: Evan Schoenberg, MD
- North Valley Eye Care (Chico, CA) Principal Investigator: Terrence Spencer, MD
- Instituto de Ojos (Carolina, PR) Principal Investigator: Miguel Santiago, MD

"The addition of these sites broadens the reach of our clinical program and reflects our commitment to advancing treatment options for patients with late-stage AMD," said Rebecca Kammer, OD, PhD, vice president, Worldwide Clinical & Medical Affairs, Samsara Vision. "We look forward to continuing the Concerto study to generate robust clinical evidence for the SING IMT."

"The American Academy of Ophthalmology meeting attracts the brightest minds in our field and it's a privilege to renew our relationships with the key investigators and providers supporting Concerto. We look forward to sharing study outcomes as they become available," said Thomas Ruggia, president and CEO of Samsara Vision.

For more information about the clinical study and participating sites, visit https://www.samsaravision.com/concerto

Addressing Unmet Treatment Needs in Late-Stage AMD

Age-related macular degeneration (AMD) is a <u>leading cause</u> of permanent vision loss for people age 50 and older, and the <u>number one cause</u> of blindness in people age 65 years and older. As many as <u>11 million</u> Americans are affected by some form of macular degeneration and this number will increase to 22 million <u>by 2050</u>. Nearly <u>2 million</u> Americans have advanced forms of AMD with associated vision loss.

The SING IMT is an intraocular telescope approved for use in patients without previous cataract surgery and 55 years and older in CE Referenced countries and is <u>under investigation</u> in the United States for patients 65 years and older meeting specific eye health criteria. There is no cure for late-stage AMD and the SING IMT[®] does not return vision to the level a patient had before AMD, nor will it completely make up for vision loss. Driving is contraindicated with the device. The most common risks of the SING IMT[®] surgery include inflammatory deposits or precipitates on the device and increased intraocular pressure. Adverse events in the recent study include corneal edema, and one patient had a decrease in visual acuity. There is a risk that having the telescope implantation surgery could worsen vision rather than improve it. Individual results may vary.

About Samsara Vision

Samsara Vision is a privately held specialty medical device company headquartered in the United States and engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. We believe that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working collaboratively with health care providers, researchers, payers, and advocates to ensure that people living with deteriorating vision have access to our novel technologies and support paths thereby better ensuring a future where they can see anew. Learn more at https://www.samsaravision.com.

Safe Harbor Statement

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. Forward-looking statements include those about the potential benefits to be derived from the SING IMT™ and the intent to work closely with the FDA to determine a timely pathway to bring the SING IMT™ to market in the United States and the belief that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. These forward-looking statements and their implications are based on the current expectations of the management of Samsara only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forwardlooking statements: claims by other companies and persons regarding ownership over intellectual property; changes in technology and market requirements; Samsara may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Samsara's products may not be approved by regulatory agencies, Samsara's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Samsara may be unable to retain or attract key employees whose

knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Samsara's process; Samsara's products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Samsara's patents may not be sufficient; Samsara's products may harm recipients; changes in legislation may adversely impact Samsara; inability to timely develop and introduce new technologies, products and applications; the risk factors and uncertainties described in the Registration Statement on Form S-1, as amended (File No. 333-260742) filed with the U.S. Securities and Exchange Commission; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Samsara to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Samsara undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251016658910/en/

Media Contact:
Jessica Daitch
JLD Communications
917-816-6712
jessica@jldcommunications.com

Source: Samsara Vision